The DOI matches its Crossref record; 110 of the 110 references it cites were found in a registry or an index.
Advances and Challenges of HDAC Inhibitors in Cancer Therapeutics
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Haberland, M., Montgomery, R. L., & Olson, E. N. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2485 · Cited by 2,526
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564
Inhibition of Histone Deacetylase Activity by Butyrate
Davie, J. R. (2003) · The Journal of Nutrition · doi:10.1093/jn/133.7.2485s · Cited by 1,515
Sirt5 Is a NAD-Dependent Protein Lysine Demalonylase and Desuccinylase
Du, J., Zhou, Y., Su, X., Yu, J. J., Khan, S., Jiang, H., Kim, J., Woo, J., Kim, J. H., Choi, B. H., et al. (2011) · Science · doi:10.1126/science.1207861 · Cited by 1,429
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
Mann, B. S., Johnson, J. R., Cohen, M. H., Justice, R., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-10-1247 · Cited by 1,365
Friend, C., Scher, W., Holland, J. G., & Sato, T. (1971) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.68.2.378 · Cited by 1,352
The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men
Yang, X.-J., & Seto, E. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2346 · Cited by 1,230
Marks, P. A., & Breslow, R. (2007) · Nature Biotechnology · doi:10.1038/nbt1272 · Cited by 1,196
Dombret, H., Seymour, J. F., Butrym, A., Wierzbowska, A., Selleslag, D., Jang, J. H., Kumar, R., Cavenagh, J., Schuh, A. C., Candoni, A., et al. (2015) · Blood · doi:10.1182/blood-2015-01-621664 · Cited by 1,165
Features and outcomes of 899 patients with drug-induced liver injury: the DILIN Prospective Study
Chalasani, N., Bonkovsky, H. L., Fontana, R., Lee, W., Stolz, A., Talwalkar, J., Reddy, K. R., Watkins, P. B., Navarro, V., Barnhart, H., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.03.006 · Cited by 925
A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
Richon, V. M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R. A., & Marks, P. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3003 · Cited by 914
Antituberculosis drug‐induced hepatotoxicity: Concise up‐to‐date review
Tostmann, A., Boeree, M. J., Aarnoutse, R. E., De Lange, W. C. M., Van Der Ven, A. J. A. M., & Dekhuijzen, R. (2008) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2007.05207.x · Cited by 781
Lysine propionylation and butyrylation are novel post-translational modifications in histones
Chen, Y., Sprung, R., Tang, Y., Ball, H., Sangras, B., Kim, S. C., Falck, J. R., Peng, J., Gu, W., & Zhao, Y. (2007) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m700021-mcp200 · Cited by 764
Chemical phylogenetics of histone deacetylases
Bradner, J. E., West, N., Grachan, M. L., Greenberg, E. F., Haggarty, S. J., Warnow, T., & Mazitschek, R. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.313 · Cited by 720
SIRT6 regulates TNF-α secretion through hydrolysis of long-chain fatty acyl lysine
Jiang, H., Khan, S., Wang, Y., Charron, G., He, B., Sebastian, C., Du, J., Kim, R., Ge, E., Mostoslavsky, R., et al. (2013) · Nature · doi:10.1038/nature12038 · Cited by 697
Erythroleukemic Differentiation
Marks, P. A., & Rifkind, R. A. (1978) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.47.070178.002223 · Cited by 680
Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases
Lahm, A., Paolini, C., Pallaoro, M., Nardi, M. C., Jones, P., Neddermann, P., Sambucini, S., Bottomley, M. J., Lo Surdo, P., Carfı́, A., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706487104 · Cited by 566
Sandor, V. A., Bakke, S., Robey, R. W., Kang, M. H., Blagosklonny, M. V., Bender, J., Brooks, R. A., Piekarz, R., Tucker, E. E., Figg, W. D., et al. (2002) · PubMed · Cited by 502
Histone deacetylases and cancer
Barneda-Zahonero, B., & Parra, M. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.07.003 · Cited by 446
Cytochrome P450 2E1 Genotype and the Susceptibility to Antituberculosis Drug–Induced Hepatitis
Huang, Y.-S., Chern, H.-D., Su, W.-J., Wu, J.-C., Chang, S.-C., Chiang, C.-H., Chang, F.-Y., & Lee, S.-D. (2003) · Hepatology · doi:10.1053/jhep.2003.50144 · Cited by 426
Second generation hybrid polar compounds are potent inducers of transformed cell differentiation.
Richon, V. M., Webb, Y., Merger, R., Sheppard, T., Jursic, B., Ngo, L., Civoli, F., Breslow, R., Rifkind, R. A., & Marks, P. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.12.5705 · Cited by 420
Ryan, Q. C., Headlee, D., Acharya, M., Sparreboom, A., Trepel, J. B., Ye, J., Figg, W. D., Hwang, K., Chung, E. J., Murgo, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.188 · Cited by 411
Byrd, J. C. (2004) · Blood · doi:10.1182/blood-2004-05-1693 · Cited by 398
Valproic acid pathway: pharmacokinetics and pharmacodynamics
Ghodke-Puranik, Y., Thorn, C. F., Lamba, J. K., Leeder, J. S., Song, W., Birnbaum, A. K., Altman, R. B., & Klein, T. E. (2013) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32835ea0b2 · Cited by 397
A new group of potent inducers of differentiation in murine erythroleukemia cells.
Reuben, R. C., Wife, R. L., Breslow, R., Rifkind, R. A., & Marks, P. A. (1976) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.73.3.862 · Cited by 370
Nolan, C. M., Goldberg, S. V., & Buskin, S. E. (1999) · JAMA · doi:10.1001/jama.281.11.1014 · Cited by 368
Galanis, E., Jaeckle, K. A., Maurer, M. J., Reid, J. M., Ames, M. M., Hardwick, J. S., Reilly, J. F., Loboda, A., Nebozhyn, M., Fantin, V. R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.0694 · Cited by 358
Identification of Novel Isoform-Selective Inhibitors within Class I Histone Deacetylases
Hu, E., Dul, E., Sung, C.-M., Chen, Z., Kirkpatrick, R., Zhang, G.-F., Johanson, K., Liu, R., Lago, A., Hofmann, G., et al. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.055541 · Cited by 347
Plumb, J. A., Finn, P. W., Williams, R. J., Bandara, M. J., Romero, M., Watkins, C. J., Thangue, N. B. L., & Brown, R. E. (2003) · PubMed · Cited by 312
Giles, F., Fischer, T., Cortes, J., Garcia-Manero, G., Beck, J., Ravandi, F., Masson, E., Rae, P., Laird, G., Sharma, S., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0511 · Cited by 312
Wei, W., Liu, X., Chen, J., Gao, S., Lu, L., Zhang, H., Ding, G., Wang, Z., Chen, Z., Shi, T., et al. (2017) · Cell Research · doi:10.1038/cr.2017.68 · Cited by 304
Synthesis and Histone Deacetylase Inhibitory Activity of New Benzamide Derivatives
Suzuki, T., Ando, T., Tsuchiya, K., Fukazawa, N., Saito, A., Mariko, Y., Yamashita, T., & Nakanishi, O. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980565u · Cited by 293
Shen, S., & Kozikowski, A. P. (2016) · ChemMedChem · doi:10.1002/cmdc.201500486 · Cited by 288
Steele, N. L., Plumb, J. A., Vidal, L., Tjørnelund, J., Knoblauch, P., Rasmussen, A., Ooi, C. E., Buhl-Jensen, P., Brown, R., Evans, T. R. J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1786 · Cited by 244
Luu, T. H., Morgan, R. J., Leong, L., Lim, D., McNamara, M., Portnow, J., Frankel, P., Smith, D. D., Doroshow, J. H., Gandara, D. R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0122 · Cited by 237
Isoniazid and Iproniazid: Activation of Metabolites to Toxic Intermediates in Man and Rat
Nelson, S. D., Mitchell, J. R., Timbrell, J. A., Snodgrass, W. R., & Corcoran, G. B. (1976) · Science · doi:10.1126/science.7838 · Cited by 226
Modesitt, S. C., Sill, M., Hoffman, J. S., & Bender, D. P. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.01.009 · Cited by 225
Use of Isoniazid for Latent Tuberculosis Infection in a Public Health Clinic
LoBue, P. A., & Moser, K. S. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200303-390oc · Cited by 224
Pimelic Diphenylamide 106 Is a Slow, Tight-binding Inhibitor of Class I Histone Deacetylases
Chou, C. J., Herman, D., & Gottesfeld, J. M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m807045200 · Cited by 223
Self-citationMechanism of isoniazid‐induced hepatotoxicity: then and now
Metushi, I., Uetrecht, J., & Phillips, E. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12885 · Cited by 217
Isoniazid Hepatotoxicity Associated With Treatment of Latent Tuberculosis Infection
Fountain, F. F., Tolley, E., Chrisman, C. R., & Self, T. H. (2005) · Chest · doi:10.1378/chest.128.1.116 · Cited by 209
Yeo, W., Chung, H. C., Chan, S. L., Wang, L. Z., Lim, R., Picus, J., Boyer, M., Mo, F. K. F., Koh, J., Rha, S. Y., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.2395 · Cited by 199
Witta, S. E., Jotte, R. M., Konduri, K., Neubauer, M. A., Spira, A. I., Ruxer, R. L., Varella-Garcia, M., Bunn, P. A., & Hirsch, F. R. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.9411 · Cited by 196
Taunton, J., Collins, J. L., & Schreiber, S. L. (1996) · Journal of the American Chemical Society · doi:10.1021/ja9615841 · Cited by 192
CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis
Vuilleumier, N., Rossier, M. F., Chiappe, A., Degoumois, F., Dayer, P., Mermillod, B., Nicod, L., Desmeules, J., & Hochstrasser, D. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0111-5 · Cited by 191
A Fresh Look at the Mechanism of Isoniazid-Induced Hepatotoxicity
Metushi, I. G., Cai, P., Zhu, X., Nakagawa, T., & Uetrecht, J. P. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.355 · Cited by 190
Giaccone, G., Rajan, A., Berman, A., Kelly, R. J., Szabo, E., Lopez-Chavez, A., Trepel, J., Lee, M.-J., Cao, L., Espinoza-Delgado, I., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.4467 · Cited by 189
Molife, L. R., Attard, G., Fong, P. C., Karavasilis, V., Reid, A. H. M., Patterson, S., Riggs, C. E., Higano, C., Stadler, W. M., McCulloch, W., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdp270 · Cited by 184
Qu, K., Zaba, L. C., Satpathy, A. T., Giresi, P. G., Li, R., Jin, Y., Armstrong, R., Jin, C., Schmitt, N., Rahbar, Z., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.05.008 · Cited by 175
Vansteenkiste, J., Van Cutsem, E., Dumez, H., Chen, C., Ricker, J. L., Randolph, S. S., & Schöffski, P. (2008) · Investigational New Drugs · doi:10.1007/s10637-008-9131-6 · Cited by 174
The novel de-long chain fatty acid function of human sirt6
Wang, Y., & Hao, Q. (2013) · Nature · doi:10.2210/pdb3zg6/pdb · Cited by 169
Blumenschein, G. R., Kies, M. S., Papadimitrakopoulou, V. A., Lu, C., Kumar, A. J., Ricker, J. L., Chiao, J. H., Chen, C., & Frankel, S. R. (2008) · Investigational New Drugs · doi:10.1007/s10637-007-9075-2 · Cited by 167
Proteomics in postgenomic neuroscience: the end of the beginning
Choudhary, J. S., & Grant, S. G. N. (2004) · Nature Neuroscience · doi:10.1038/nn1240 · Cited by 163
Isoniazid hepatoxicity: the relationship between covalent binding and metabolism in vivo.
Timbrell, J. A., Mitchell, J. R., Snodgrass, W. R., & Nelson, S. D. (1980) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)32069-0 · Cited by 161
MacKay, H. J., Hirte, H. W., Colgan, T. J., Covens, A., MacAlpine, K., Grenci, P., Wang, L. E., Mason, J., Pham, P.-A., Tsao, M., et al. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.047 · Cited by 160
Induction of transformed cells to terminal differentiation and the modulation of gene expression.
Marks, P. A., Sheffery, M., & Rifkind, R. A. (1987) · PubMed · Cited by 160
Ramalingam, S. S., Belani, C. P., Ruel, C., Frankel, P., Gitlitz, B., Koczywas, M., Espinoza-Delgado, I., & Gandara, D. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318191520c · Cited by 159
Mitochondrial Involvement in Drug-Induced Liver Injury
Pessayre, D., Mansouri, A., Berson, A., & Fromenty, B. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-00663-0_11 · Cited by 154
Woyach, J. A., Kloos, R. T., Ringel, M. D., Arbogast, D., Collamore, M., Zwiebel, J. A., Grever, M. R., Villalona-Calero, M. A., & Shah, M. H. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1631 · Cited by 154
A Phase II Study of Depsipeptide in Refractory Metastatic Renal Cell Cancer
Stadler, W. M., Margolin, K. A., Ferber, S., McCulloch, W. F., & Thompson, J. A. (2006) · Clinical Genitourinary Cancer · doi:10.3816/cgc.2006.n.018 · Cited by 151
Regulatory signal transduction pathways for class IIa histone deacetylases
Parra, M., & Verdin, E. M. (2010) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2010.04.004 · Cited by 147
Pyrazinamide and Rifampin vs Isoniazid for the Treatment of Latent Tuberculosis
McNeill, L., Allen, M. G., Estrada, C. A., & Cook, P. (2003) · CHEST Journal · doi:10.1378/chest.123.1.102 · Cited by 135
A phase 2 study of vorinostat in acute myeloid leukemia
Schaefer, É., Loaiza‐Bonilla, A., Juckett, M. B., DiPersio, J. F., Roy, V., Slack, J. L., Wu, W., Laumann, K. M., Espinoza‐Delgado, I., & Gore, S. D. (2009) · Haematologica · doi:10.3324/haematol.2009.009217 · Cited by 128
Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin
Schrump, D. S., Fischette, M. R., Nguyen, D. M., Zhao, M., Li, X., Kunst, T. F., Hancox, A., Hong, J. A., Chen, G. A., Kruchin, E., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0135 · Cited by 126
IWAMOTO, F. M., Lamborn, K. R., Kuhn, J. G., Wen, P. Y., Yung, W. K. A., Gilbert, M. R., Chang, S. M., Lieberman, F. S., Prados, M. D., & Fine, H. A. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor017 · Cited by 126
Andreeff, M., Stone, R. M., Michaeli, J., Cw, Y., Tong, W., Sogoloff, H., Ervin, T. J., Kufe, D. W., Rifkind, R. A., & Marks, P. (1992) · Blood · doi:10.1182/blood.v80.10.2604.2604 · Cited by 124
Lee, S.-W., Chung, L. S.-C., Huang, H.-H., Chuang, T.-Y., Liou, Y.-H., & Wu, L. (2010) · PubMed · Cited by 123
Madsen, A. S., & Olsen, C. A. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201203754 · Cited by 122
Wang, Y., Stowe, R. L., Pinello, C. E., Tian, G., Madoux, F., Li, D., Zhao, L. Y., Li, J.-L., Wang, Y., Wang, Y., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.12.015 · Cited by 122
HDAC8 catalyzes the hydrolysis of long chain fatty acyl lysine
Aramsangtienchai, P., Spiegelman, N. A., He, B., Miller, S. P., Dai, L., Zhao, Y., & Lin, H. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00396 · Cited by 118
Rubin, E. H., Agrawal, N. G. B., Friedman, E. J., Scott, P., Mazina, K. E., Sun, L., Du, L., Ricker, J. L., Frankel, S. R., Gottesdiener, K. M., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1802 · Cited by 115
McClure, J. J., Zhang, C., Inks, E. S., Peterson, Y. K., Li, J., & Chou, C. J. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01385 · Cited by 112
Dizon, D. S., Blessing, J. A., Penson, R. T., Drake, R. D., Walker, J. L., Johnston, C. M., DiSilvestro, P., & Fader, A. N. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.02.019 · Cited by 102
Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin
Schrump, D. S., Fischette, M. R., Nguyen, D. M., Zhao, M., Li, X., Kunst, T. F., Hancox, A., Hong, J. A., Chen, G. A., Kruchin, E., et al. (2007) · Clinical Lung Cancer · doi:10.1016/s1525-7304(11)70818-x · Cited by 97
Association of NAT2, GST and CYP2E1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity
Singla, N., Gupta, D., Birbian, N., & Singh, J. (2014) · Tuberculosis · doi:10.1016/j.tube.2014.02.003 · Cited by 95
Wang, H., Yu, N., Chen, D., Lee, K. C. L., Lye, P. L., Chang, J. W. W., Deng, W., Ng, M., Lu, T., Khoo, M. L., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2003552 · Cited by 94
Haigentz, M., Kim, M., Sarta, C., Lin, J., Keresztes, R. S., Culliney, B. E., Gaba, A. G., Smith, R. V., Shapiro, G. I., Chirieac, L. R., et al. (2012) · Oral Oncology · doi:10.1016/j.oraloncology.2012.05.024 · Cited by 90
Lassen, U., Molife, L. R., Mau‐Sørensen, M., Engelholm, S. A., Vidal, L., Sinha, R., Penson, R. T., Buhl-Jensen, P., Crowley, E. M., Tjørnelund, J., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605726 · Cited by 89
Hainsworth, J. D., Infante, J. R., Spigel, D. R., Arrowsmith, E. R., Boccia, R. V., & Burris, H. A. (2011) · Cancer Investigation · doi:10.3109/07357907.2011.590568 · Cited by 88
Graham, C. L., Tucker, C., Creech, J., Favours, E., Billups, C. A., Liu, T., Fouladi, M., Freeman, B. B., Stewart, C. F., & Houghton, P. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1225 · Cited by 87
Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma
Drappatz, J., Lee, E. Q., Hammond, S., Grimm, S. A., Norden, A. D., Beroukhim, R., Gerard, M., Schiff, D., S., A., Batchelor, T. T., et al. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0717-z · Cited by 81
Hauschild, A., Trefzer, U., Garbe, C., Kaehler, K. C., Ugurel, S., Kiecker, F., Eigentler, T., Krissel, H., Schott, A., & Schadendorf, D. (2008) · Melanoma Research · doi:10.1097/cmr.0b013e328307c248 · Cited by 80
Whitehead, R. P., Rankin, C. J., Hoff, P. M., Gold, P. J., Billingsley, K. G., Chapman, R., Wong, L., Ward, J. H., Abbruzzese, J. L., & Blanke, C. D. (2008) · Investigational New Drugs · doi:10.1007/s10637-008-9190-8 · Cited by 80
Xiao, J. J., Foraker, A. B., Swaan, P. W., Liu, S., Huang, Y. S., Zunyan Dai, Y., Chen, J., Sadée, W., Byrd, J. C., Marcucci, G., et al. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.072033 · Cited by 74
Otterson, G. A., Hodgson, L. C., Pang, H., & Vokes, E. E. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181ec1713 · Cited by 72
Drug Development - A Case Study Based Insight into Modern Strategies
Rundfeldt, C. (2011) · InTech eBooks · doi:10.5772/2435 · Cited by 70
Sherman, E. J., Su, Y. B., Lyall, A., Schöder, H. M., Fury, M. G., Ghossein, R. A., Haque, S. S., Lisa, D., Shaha, A. R., Tuttle, R. M., et al. (2012) · Thyroid · doi:10.1089/thy.2012.0393 · Cited by 69
Balliet, R. M., Chen, G., Gallagher, C. J., Dellinger, R. W., Sun, D., & Lazarus, P. J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4143 · Cited by 68
Wang, L.-Z., Ramı́rez, J., Yeo, W., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054522 · Cited by 66
Al‐Yacoub, N., Fecker, L. F., Möbs, M., Plötz, M., Braun, F., Sterry, W., & Eberle, J. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.125 · Cited by 61
Hepatotoxicity and metabolism of iproniazid and isopropylhydrazine.
Nelson, S. D., Mitchell, J. R., Snodgrass, W. R., & Timbrell, J. A. (1978) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)31362-5 · Cited by 57
Steele, N. L., Plumb, J. A., Vidal, L., Tjørnelund, J., Knoblauch, P., Buhl-Jensen, P., Molife, R., Brown, R. E., Bono, J. S. D., & Evans, T. R. J. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1419-5 · Cited by 57
Wang, H., Cao, Q., & Dudek, A. Z. (2012) · PubMed · Cited by 55
Jones, S. F., Infante, J. R., Spigel, D. R., Peacock, N. W., Thompson, D. S., Greco, F. A., McCulloch, W. F., & Burris, H. A. (2012) · Cancer Investigation · doi:10.3109/07357907.2012.675382 · Cited by 54
Comparison of the Deacylase and Deacetylase Activity of Zinc-Dependent HDACs
McClure, J. J., Inks, E. S., Zhang, C., Peterson, Y. K., Li, J., Chundru, K. J., Lee, B., Buchanan, A., Miao, S., & Chou, C. J. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00321 · Cited by 53
Chang, T.-E., Huang, Y., Chang, C.-H., Perng, C., Huang, Y., & Hou, M. (2017) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2017.10.002 · Cited by 46
Hayashi, P. H., Fontana, R. J., Chalasani, N. P., Stolz, A. A., Talwalkar, J. A., Navarro, V. J., Lee, W. M., Davern, T. J., Kleiner, D. E., Gu, J., et al. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.02.024 · Cited by 45
Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors
Strickler, J. H., Starodub, A., Jia, J., Meadows, K. L., Nixon, A. B., Dellinger, A. E., Morse, M. A., Uronis, H. E., Marcom, P. K., Zafar, S. Y., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1911-1 · Cited by 44
Sheng, Y., Wu, G., He, H., Chen, W., Zou, Y., Li, Q., Zhong, L., Huang, Y., & Deng, C. (2014) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2014.01.034 · Cited by 41
The p53 isoform delta133p53ß regulates cancer cell apoptosis in a RhoB-dependent manner
Arsic, N., Ho-Pun-Cheung, A., Lopez‐Crapez, E., Assénat, E., Jarlier, M., Anguille, C., Manon, C., Pezet, M. G., Roux, P., & Gadéa, G. (2017) · PLoS ONE · doi:10.1371/journal.pone.0172125 · Cited by 41
A phase I study of panobinostat in combination with gemcitabine in the treatment of solid tumors.
Jones, S. F., Bendell, J. C., Infante, J. R., Spigel, D. R., Thompson, D. S., Yardley, D. A., Greco, F., Murphy, P. B., & Burris, H. A. (2011) · PubMed · Cited by 40
Shiraga, T., Tozuka, Z., Ishimura, R., Kawamura, A., & Kagayama, A. (2005) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.28.124 · Cited by 38
ORIGINAL ARTICLE: Solubilization of vorinostat by cyclodextrins
Cai, Y., Yap, C. W., Wang, Z., Ho, P. C., Chan, S. Y., Ng, K. Y., Ge, Z., & Lin, H. (2009) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2009.01095.x · Cited by 37
Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor
Acharya, M. R., Sparreboom, A., Sausville, E. A., Conley, B. A., Doroshow, J. H., Venitz, J., & Figg, W. D. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-0058-8 · Cited by 36
Identification of a tumor-derived p53 mutant with novel transactivating selectivity
Pan, Y., & Haines, D. S. (2000) · Oncogene · doi:10.1038/sj.onc.1203663 · Cited by 28
Warren, K. E., McCully, C. L., Dvinge, H., Tjørnelund, J., Sehested, M., Lichenstein, H. S., & Balis, F. M. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0622-5 · Cited by 27
Young, H. L., Wessolossky, M., Ellis, J., Kaminski, M., & Daly, J. S. (2009) · Clinical Infectious Diseases · doi:10.1086/600394 · Cited by 27
Konsoula, Z., Cao, H., Velena, A., & Jung, M. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0629 · Cited by 27
Rodríguez‐Paredes, M., & Esteller, M. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0271 · Cited by 23
Ethirajulu, K., & Jayaram, R. (2011) · InTech eBooks · doi:10.5772/27799 · Cited by 8
Cited by
Toward Multi-Targeted Platinum and Ruthenium Drugs—A New Paradigm in Cancer Drug Treatment Regimens?
Kenny, R. G., & Marmion, C. J. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00271 · Cited by 636
Recent developments of HDAC inhibitors: Emerging indications and novel molecules
Bondarev, A. D., Attwood, M. M., Jonsson, J., Chubarev, V. N., Tarasov, V. V., & Schiöth, H. B. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14889 · Cited by 416
Cancer Epigenetics, Tumor Immunity, and Immunotherapy
Cao, J., & Yan, Q. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.02.003 · Cited by 346
Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy
Ramaiah, M. J., Tangutur, A. D., & Manyam, R. R. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119504 · Cited by 345
Epigenetic modulation of antitumor immunity for improved cancer immunotherapy
Dai, E., Zhu, Z., Wahed, S., Qu, Z., Storkus, W. J., & Guo, Z. S. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01464-x · Cited by 328
Metadata
- Venue
- Advances in Cancer Research
- Publisher
- Elsevier
- Published
- 2018
- Volume
- 138
- Pages
- 183-211
- ISSN
- 0065-230X (ISSN-L)
- OpenAlex
- W2792323180
- Cited by
- 352
- References
- 110
- FWCI
- 42.04
- Type
- book chapter
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.